Marian Hannan Celebrated after 10 Years as AC&R Editor-in-Chief By Kelly April Tyrrell This summer, the 10-year tenure of Marian Hannan, MPH, DSc, as editor in chief of Arthritis Care & Research (AC&R), has come to an end. Kelli Allen, PhD, assumed the post on July 1. “Marian has done a fantastic job over the…
On Sept. 1, the U.S. Food & Drug Administration (FDA) announced that it is requiring revisions to the Boxed Warning for the Janus kinase (JAK) inhibitors Xeljanz/Xeljanz XR (tofacitinib), Olumiant (baricitinib) and Rinvoq (upadacitinib) to include information about the risks of serious heart-related events, cancer, blood clots and death.1 Recommendations for healthcare professionals will include…
Data from a single-center registry shines light on 20 years of trends in first-line, biologic disease-modifying anti-rheumatic drug prescriptions for patients with rheumatoid arthritis.
In a study, Janus kinase inhibitors proved effective for patients with difficult-to-treat rheumatoid arthritis (RA).
In early June, the ACR released an updated guideline on the management of rheumatoid arthritis, which includes new recommendations for specific high-risk groups.1 The guideline includes 44 recommendations—seven of which are strong and 37 conditional. It underscores the role of methotrexate as a cornerstone therapy and emphasizes minimizing glucocorticoids, when possible. Guideline Development Process At…
Advancements in the treatment of myositis are on their way, according to Hector Chenoy, PhD, FRCP, who outlined the latest clinical trials during the 2021 ACR State-of-the-Art Clinical Symposium.
Patients with autoimmune diseases, such as spondyloarthritis, are at risk of developing inflammatory bowel disease. Here are considerations for its management and treatment.
Spurred by a recent Cigna policy, the ACR will lead a resolution to oppose insurance companies providing financial incentives for patients to switch treatments. Several specialties are cosponsoring the resolution for a special meeting of the AMA House of Delegates in June.
A 61-year-old white woman presented to our rheumatology clinic in New England to establish care in early June 2018, following a move from Texas. She reported a medical history of inflammatory bowel disease, uveitis and seroÂnegative inflammatory arthritis, which was difficult to control and required the use of multiple medications. At her initial visit, she…
The ACR has sent a letter to Cigna expressing opposition to the initiative, which jeopardizes patients’ health, interferes with medical decision making, undermines the doctor-patient relationship and may disproportionately affect patients of lower socioeconomic status.